RU2015106916A - Полипептиды clostridium difficile в виде вакцины - Google Patents
Полипептиды clostridium difficile в виде вакцины Download PDFInfo
- Publication number
- RU2015106916A RU2015106916A RU2015106916A RU2015106916A RU2015106916A RU 2015106916 A RU2015106916 A RU 2015106916A RU 2015106916 A RU2015106916 A RU 2015106916A RU 2015106916 A RU2015106916 A RU 2015106916A RU 2015106916 A RU2015106916 A RU 2015106916A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- antigen
- polypeptide
- immunogenic composition
- toxa
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract 23
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 23
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 23
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract 13
- 229960005486 vaccine Drugs 0.000 title claims 8
- 239000000427 antigen Substances 0.000 claims abstract 38
- 102000036639 antigens Human genes 0.000 claims abstract 38
- 108091007433 antigens Proteins 0.000 claims abstract 38
- 230000002163 immunogen Effects 0.000 claims abstract 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 9
- 239000012634 fragment Substances 0.000 claims abstract 9
- 150000001413 amino acids Chemical class 0.000 claims abstract 7
- 102000039446 nucleic acids Human genes 0.000 claims abstract 4
- 108020004707 nucleic acids Proteins 0.000 claims abstract 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 4
- 241000124008 Mammalia Species 0.000 claims 7
- 230000028993 immune response Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010061819 Disease recurrence Diseases 0.000 claims 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 1
- 101710182223 Toxin B Proteins 0.000 claims 1
- 101710182532 Toxin a Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1216749.0 | 2012-09-19 | ||
| GB201216748A GB201216748D0 (en) | 2012-09-19 | 2012-09-19 | Methods of treatment |
| GB1216748.2 | 2012-09-19 | ||
| GB201216749A GB201216749D0 (en) | 2012-09-19 | 2012-09-19 | Antigen combinations |
| PCT/IB2013/058673 WO2014045226A1 (en) | 2012-09-19 | 2013-09-19 | Clostridium difficile polypeptides as vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015106916A true RU2015106916A (ru) | 2016-11-10 |
Family
ID=49725168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015106916A RU2015106916A (ru) | 2012-09-19 | 2013-09-19 | Полипептиды clostridium difficile в виде вакцины |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9932374B2 (enExample) |
| EP (1) | EP2897637A1 (enExample) |
| JP (1) | JP2015529677A (enExample) |
| KR (1) | KR20150056540A (enExample) |
| CN (1) | CN104582722A (enExample) |
| AU (1) | AU2013319821A1 (enExample) |
| BR (1) | BR112015004629A2 (enExample) |
| CA (1) | CA2882620A1 (enExample) |
| IL (1) | IL237172A0 (enExample) |
| MX (1) | MX2015002485A (enExample) |
| RU (1) | RU2015106916A (enExample) |
| SG (1) | SG11201500980WA (enExample) |
| WO (1) | WO2014045226A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391236B (es) | 2011-04-22 | 2025-03-21 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| GB2525177A (en) * | 2014-04-14 | 2015-10-21 | New Royal Holloway & Bedford | Vaccine |
| ES2870506T3 (es) | 2015-02-19 | 2021-10-27 | Immune Biosolutions Inc | Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| EP3810163A1 (en) | 2018-06-19 | 2021-04-28 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| EP1268774A2 (en) * | 2000-03-21 | 2003-01-02 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
| WO2001094599A1 (en) * | 2000-06-07 | 2001-12-13 | Smittskyddsinstitutet | Gene expression cassette and its use |
| WO2002077183A2 (en) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| AU2003299527A1 (en) * | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
| EP2167119B1 (en) * | 2007-06-14 | 2016-08-24 | The Secretary of State for Health | Chemically modified peptides with improved immunogenicity |
| CA2714720A1 (en) * | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| EP2519257A4 (en) * | 2009-12-02 | 2014-10-15 | Univ Tufts | ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS |
| SG11201402375VA (en) | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
-
2013
- 2013-09-19 BR BR112015004629A patent/BR112015004629A2/pt not_active IP Right Cessation
- 2013-09-19 WO PCT/IB2013/058673 patent/WO2014045226A1/en not_active Ceased
- 2013-09-19 CA CA2882620A patent/CA2882620A1/en active Pending
- 2013-09-19 US US14/425,037 patent/US9932374B2/en active Active
- 2013-09-19 KR KR1020157005022A patent/KR20150056540A/ko not_active Withdrawn
- 2013-09-19 MX MX2015002485A patent/MX2015002485A/es unknown
- 2013-09-19 SG SG11201500980WA patent/SG11201500980WA/en unknown
- 2013-09-19 AU AU2013319821A patent/AU2013319821A1/en not_active Abandoned
- 2013-09-19 JP JP2015531683A patent/JP2015529677A/ja active Pending
- 2013-09-19 RU RU2015106916A patent/RU2015106916A/ru not_active Application Discontinuation
- 2013-09-19 CN CN201380045505.3A patent/CN104582722A/zh active Pending
- 2013-09-19 EP EP13802107.6A patent/EP2897637A1/en active Pending
-
2015
- 2015-02-10 IL IL237172A patent/IL237172A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015529677A (ja) | 2015-10-08 |
| EP2897637A1 (en) | 2015-07-29 |
| AU2013319821A1 (en) | 2015-02-26 |
| US9932374B2 (en) | 2018-04-03 |
| KR20150056540A (ko) | 2015-05-26 |
| BR112015004629A2 (pt) | 2017-11-21 |
| MX2015002485A (es) | 2015-06-05 |
| US20150315248A1 (en) | 2015-11-05 |
| SG11201500980WA (en) | 2015-04-29 |
| IL237172A0 (en) | 2015-04-30 |
| WO2014045226A1 (en) | 2014-03-27 |
| CA2882620A1 (en) | 2014-03-27 |
| CN104582722A (zh) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| RU2508126C2 (ru) | Композиции для иммунизации против staphylococcus aureus | |
| BR112014030797A2 (pt) | epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| MY173004A (en) | Mycobacterial antigen vaccine | |
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| JP2012523246A5 (enExample) | ||
| JP2016504993A5 (enExample) | ||
| SI2714910T1 (en) | An immunogenic composition | |
| JP2015500827A5 (enExample) | ||
| JP2015529677A5 (enExample) | ||
| CA2901888C (en) | Influenza nucleoprotein vaccines | |
| RU2016133598A (ru) | Композиция микобактериального антигена | |
| Sharma et al. | Identification and immunogenic potential of B cell epitopes of outer membrane protein OmpF of Aeromonas hydrophila in translational fusion with a carrier protein | |
| CN113577257B (zh) | 细粒棘球绦虫EgTeg和EgFABP1多表位疫苗及应用 | |
| WO2009074861A3 (en) | Improved vaccine | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
| TWI693231B (zh) | 豬胸膜肺炎放線桿菌重組毒素蛋白及其應用 | |
| CN104059134B (zh) | 败血性巴氏杆菌毒素重组蛋白及其应用 | |
| Walczak et al. | Method for generation of peptide‐specific igy antibodies directed to Staphylococcus aureus extracellular fibrinogen binding protein epitope | |
| CN106692963A (zh) | 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗 | |
| RU2015125699A (ru) | Антигены и комбинации антигенов pseudomonas | |
| Xiong et al. | A porcine reproductive and respiratory syndrome virus (PRRSV) vaccine candidate based on the fusion protein of PRRSV glycoprotein 5 and the Toll-like Receptor-5 agonist Salmonella Typhimurium FljB | |
| RU2013135002A (ru) | Вакцинный антиген бабезиоза собак |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171107 |